NVCT
Nuvectis Pharma, Inc.NASDAQHealthcare$7.56-0.53%ClosedMarket Cap: $200.3M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
9.06
P/S
0.00
EV/EBITDA
-6.20
DCF Value
$1.18
FCF Yield
-7.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-131.8%
ROA
-83.4%
ROIC
-149.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-7.3M | $-0.31 |
| FY 2025 | $0.00 | $-26.4M | $-1.32 |
| Q3 2025 | $0.00 | $-7.5M | $-0.44 |
| Q2 2025 | $0.00 | $-6.3M | $-0.30 |
Analyst Ratings
View AllHC Wainwright & Co.Buy
2025-08-04HC Wainwright & Co.Buy
2025-04-30Trading Activity
Insider Trades
View AllShemesh Shayofficer: Chief Dev. & Ops. Officer
SellFri Jan 09
BENTSUR RONdirector, 10 percent owner, officer: Chairman & CEO
SellFri Jan 09
Poradosu Enriqueofficer: Chief Science & Business Off
SellFri Jan 09
Carson Michael J.officer: Vice President, Finance
SellFri Jan 09
BENTSUR RONdirector, 10 percent owner, officer: Chairman & CEO
BuyThu Nov 06
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-0.21
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.